Received Nov 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
neurological problems; This non-serious case was reported by a consumer via call center representative and described the occurrence of neurological disorder nos in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included ZOSTAVAX. On an unknown date, the patients received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced neurological disorder nos (Verbatim: neurological problems). The outcome of the neurological disorder nos was unknown. It was unknown if the reporter considered the neurological disorder nos to be related to Shingrix. It was unknown if the company considered the neurological disorder nos to be related to Shingrix. Additional Information: GSK Receipt Date: 23-OCT-2025 Consumer reported that her doctor told her that she had lots of patients that had neurological problems after administration of Shingrix. The doctor had mentioned of patients also having had Zostavax administered, it was unknown, if the doctor meant patients that had Zostavax and then Shingrix administered or only patients that received Shingrix. No further information was provided. The batch number was not provided, and we are unable to contact the reporter.